Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. experienced a significant stock price fluctuation, with a cumulative closing price increase exceeding 30% over three consecutive trading days from August 18 to August 20, 2025, indicating abnormal trading activity [2][3]. Group 1: Stock Trading Abnormalities - The company's stock price closed at 33.11 yuan per share as of August 20, 2025, with a recent cumulative increase that surpasses most peers in the industry and the Shanghai Composite Index [2][9]. - The rolling price-to-earnings (P/E) ratio for the company is reported at 338.72, significantly deviating from the industry average P/E ratio of 32.11 for the pharmaceutical manufacturing sector [2][9]. Group 2: Company Operations and Confirmations - The company conducted a self-examination and confirmed that its daily operations remain normal, with no significant changes or major events affecting its business [4][5]. - There are no undisclosed significant matters or ongoing major asset restructuring, share issuance, or other substantial corporate actions as of the announcement date [5][8]. Group 3: Market and Media Influence - The company has not identified any media reports or market rumors that could have significantly impacted its stock price, nor any leaks of undisclosed major information by company personnel [6][7].

Core Viewpoint - The stock of Taihao Technology Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative closing price increase of 20% over three consecutive trading days from August 18 to August 20, 2025, which is classified as an abnormal trading situation according to the Shanghai Stock Exchange rules [2][4]. Group 1: Stock Trading Abnormality - The stock price deviation reached a cumulative increase of 20% over three consecutive trading days [2][4]. - The company confirmed that its main business and production operations are normal, with no significant changes in market conditions or industry policies [2][5]. Group 2: Company Verification and Major Events - The company is planning to acquire a 27.46% stake in its subsidiary, Taihao Military Industry, through a share issuance [3][7]. - The first major shareholder, Tongfang Co., Ltd., confirmed that there are no undisclosed significant matters related to the company [7][12]. Group 3: Media Reports and Market Rumors - The company has not identified any media reports or market rumors that could significantly impact its stock price [8][9]. Group 4: Board of Directors Statement - The board of directors confirmed that there are no undisclosed matters that should be disclosed according to the relevant regulations of the Shanghai Stock Exchange [12].

Core Viewpoint - The company, Yazhen Home Co., Ltd., has experienced a significant stock price fluctuation, leading to a temporary suspension of trading to protect investor interests. The stock will resume trading on August 21, 2025, after a thorough review of its trading activities and financial performance [2][3][13]. Group 1: Stock Trading and Suspension - The company's stock price increased by 33.92% from July 30 to August 6, 2025, significantly deviating from the Shanghai Composite Index and the furniture manufacturing industry [2][3]. - The stock was suspended from trading on August 7, 2025, for a period not exceeding 10 trading days, to conduct a review of the trading situation [3][13]. - The stock will resume trading on August 21, 2025, following the completion of the review [3][13]. Group 2: Financial Performance - For the fiscal year 2024, the company reported total revenue of 202.40 million yuan, with a net loss attributable to shareholders of 116.96 million yuan [4][9]. - The company expects a net loss for the first half of 2025 to be between 39.50 million yuan and 33.00 million yuan [4][9]. - The company has been placed under delisting risk warning since May 6, 2025, due to its financial performance [4][9]. Group 3: Acquisition and Business Development - The company plans to acquire 51% of Guangxi Zirconium Industry Technology Co., Ltd. from Hainan Zirconium Titanium Resources Holdings Group Co., Ltd. for 55.45 million yuan [5][15]. - As of August 20, 2025, the acquisition has been completed, and Guangxi Zirconium has become a subsidiary of the company [5][16]. - The company has initiated the pledge procedures for the acquired shares, which have been successfully registered [18].

Group 1 - The company's stock price experienced an abnormal fluctuation, with a cumulative increase of over 20% in closing prices over three consecutive trading days (August 15, 18, and 19, 2025) [2] - The board of directors confirmed that there are no corrections or supplements needed for previously disclosed information, and the company's current operating conditions are normal without significant changes in the internal or external business environment [2][3] - The company and its controlling shareholders have not engaged in any undisclosed significant matters related to the company during the period of stock price fluctuation [2][3] Group 2 - The board of directors confirmed that there are no undisclosed matters that should have been disclosed according to the Shenzhen Stock Exchange listing rules, nor any related planning, discussions, or agreements that could significantly impact the company's stock price [3] - The company has conducted a self-examination and confirmed compliance with fair information disclosure regulations, indicating no violations [4]

Core Viewpoint - Oulin Bio (688319) experienced a significant stock price increase, with a cumulative rise of over 30% in three consecutive trading days, leading to a classification of abnormal trading activity [1] Company Summary - Oulin Bio confirmed that its daily operations are normal and there have been no significant changes in its business [1] - The company conducted inquiries with its controlling shareholder and actual controller, confirming that there are no undisclosed major information as of the announcement date [1] - The recent stock price increase of Oulin Bio has outpaced most of its industry peers and the Shanghai Composite Index, indicating a potential short-term market overheating risk [1]

Core Viewpoint - *ST Songfa's stock price has experienced significant fluctuations, with a cumulative increase of 15.3% over three trading days, contrasting with the market's 1.88% rise, indicating potential investor interest and market volatility [1] Group 1: Stock Performance - The stock price of *ST Songfa increased by 15.3% from August 18 to August 20, while the overall market rose by 1.88% during the same period [1] - As of the close on August 20, *ST Songfa's stock was priced at 59.3 yuan per share, resulting in a total market capitalization of 575.7 billion yuan [1] Group 2: Company Announcements - The company disclosed that it has not identified any undisclosed significant information aside from what has already been made public [1] - *ST Songfa has undergone a major asset restructuring, with the completion of related transactions expected by May 2025 and the registration of new shares by August 18, 2025 [1] Group 3: Business Transformation - The company's main business has shifted from ceramic manufacturing to the research, development, production, and sales of ships and high-end equipment [1]

Core Viewpoint - The stock of VeriSilicon Limited has experienced significant volatility, with a cumulative price deviation exceeding 30% over three consecutive trading days, but the company confirms that its operations remain stable and there are no undisclosed significant events [1] Group 1: Stock Performance - The stock price of the company has shown abnormal fluctuations, with a cumulative increase of over 30% in the last three trading days [1] - The first major shareholder, VeriSilicon Limited, has confirmed that there are no undisclosed significant information as of the announcement date [1] Group 2: Business Operations - The company reports that all production and operational activities are normal, with no significant changes occurring [1] - As of the end of the first quarter of 2025, the company expects to have an order backlog amounting to 3.025 billion yuan, which represents a 23.17% increase compared to the end of the first quarter of 2025, marking a historical high for the company [1]

电子城公告，公司股票于2025年8月18日、8月19日、8月20日连续3个交易日内日收盘价格涨幅偏离值累 计超过20%，属于《上海证券交易所交易规则》规定的股票交易异常波动情形。经公司自查并向控股股 东征询确认，截至本公告披露日，除已披露的信息外，公司、控股股东不存在影响公司股票交易异常波 动的应披露而未披露的重大信息。公司股票价格短期内涨幅较大，敬请广大投资者注意二级市场交易风 险，审慎决策，理性投资。 ...

Core Viewpoint - The stock price of Nord New Materials Co., Ltd. experienced an abnormal fluctuation, with a cumulative increase of 20% over three consecutive trading days in August 2025, prompting regulatory scrutiny [2][4]. Group 1: Stock Trading Abnormalities - The company's stock price rose by a cumulative 20% on August 15, 18, and 19, 2025, indicating abnormal trading behavior as per Shanghai Stock Exchange regulations [2][4]. - The stock price increased by 33.18% from August 14 to August 19, 2025, while the relevant industry index only rose by 3.99% during the same period [8]. Group 2: Financial Performance - In 2024, the company reported a revenue of 5.277 billion, a year-on-year increase of 15.44%, but incurred a net loss of 352 million [5]. - For the first quarter of 2025, the company achieved a revenue of 1.409 billion but reported a net loss of 38 million [5]. - Preliminary estimates suggest a net loss of approximately 70 million for the first half of 2025, with a net loss of around 82 million after excluding non-recurring items [5]. Group 3: Regulatory Issues - The company and its chairman, along with other executives, received a notice from the China Securities Regulatory Commission regarding suspected violations of information disclosure laws [3][9]. - The company is cooperating with the investigation and has not yet received a conclusive opinion on the matter [9]. Group 4: Management Assurance - The board of directors confirmed that there are no undisclosed significant matters that could affect stock trading, and all required disclosures have been made [12].

Core Viewpoint - The stock of Jimin Health Management Co., Ltd. experienced abnormal trading fluctuations, with a cumulative closing price increase exceeding 20% over two consecutive trading days, prompting a risk warning to investors [2][3]. Group 1: Stock Trading Abnormalities - The company's stock price increased by 53.78% from August 13 to August 19, 2025, with significant deviations from the market and sector trends [2][7]. - The stock's closing price deviation reached a cumulative value of 20% on August 18 and 19, 2025, qualifying as an abnormal trading situation under the Shanghai Stock Exchange rules [3][4]. Group 2: Company Verification and Confirmation - The company conducted a self-examination and confirmed that there were no significant changes in its main business or external operating environment, and no undisclosed major matters exist [4][5]. - The company received written confirmation from its controlling shareholder and actual controller, stating that there are no undisclosed major asset restructurings, share issuances, or significant transactions [4][5]. Group 3: Financial Performance Risks - The company reported a net loss of 59.71 million yuan for the fiscal year 2024 and anticipates a net loss between 55 million yuan and 46 million yuan for the first half of 2025, indicating a decline compared to the previous year [2][7]. - The recent stock price increase is not aligned with the company's fundamental performance, suggesting a risk of short-term price correction [2][7].